Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL
- PMID: 37820294
- PMCID: PMC10730082
- DOI: 10.1200/JCO.23.01286
Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL
Abstract
Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the survival rate of children with ALL. In the past two decades, the use of minimal (measurable) residual disease (MRD) measurements early in therapy improved risk group stratification with subsequent treatment intensifications for patients at high risk of relapse, and enabled a reduction of treatment for low-risk patients. The recent development of more sensitive MRD technologies may further affect risk stratification. Molecular genetic profiling has led to the discovery of many new subtypes and their driver genetic alterations. This increased our understanding of the biological basis of ALL, improved risk classification, and enabled implementation of precision medicine. In the past decade, immunotherapies, including bispecific antibodies, antibody-drug conjugates, and cellular therapies directed against surface proteins, led to more effective and less toxic therapies, replacing intensive chemotherapy courses and allogeneic stem-cell transplantation in patients with relapsed and refractory ALL, and are now being tested in newly diagnosed patients. It has taken 50-60 years to increase the cure rate in childhood ALL from 0% to 90% by stepwise improvements in chemotherapy. This review provides an overview of how the developments over the past 10-15 years mentioned above have significantly changed the diagnostic and treatment approach in ALL, and discusses how the integrated use of molecular and immunotherapeutic insights will very likely direct efforts to cure those children with ALL who are not cured today, and improve the quality of life for survivors who should have decades of life ahead. Future efforts must focus on making effective, yet very expensive, new technologies and therapies available to children with ALL worldwide.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
No other potential conflicts of interest were reported.
Figures




Similar articles
-
[Acute leukemia in adults].Pathologe. 2015 Sep;36(5):503-17; quiz 518-9. doi: 10.1007/s00292-015-0087-y. Pathologe. 2015. PMID: 26314268 Review. German.
-
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.Klin Padiatr. 2013 May;225 Suppl 1:S73-8. doi: 10.1055/s-0033-1337967. Epub 2013 May 22. Klin Padiatr. 2013. PMID: 23700062
-
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.J Immunother Cancer. 2020 May;8(1):e000630. doi: 10.1136/jitc-2020-000630. J Immunother Cancer. 2020. PMID: 32439800 Free PMC article.
-
Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.Dtsch Arztebl Int. 2012 Oct;109(40):652-8. doi: 10.3238/arztebl.2012.0652. Epub 2012 Oct 5. Dtsch Arztebl Int. 2012. PMID: 23094001 Free PMC article.
-
Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.Haematologica. 2000 Nov;85(11 Suppl):47-53. Haematologica. 2000. PMID: 11268324 Review.
Cited by
-
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia.Blood Cancer J. 2024 Aug 28;14(1):150. doi: 10.1038/s41408-024-01122-7. Blood Cancer J. 2024. PMID: 39198413 Free PMC article.
-
New precision medicine weapons for targeted treatment of high-risk B-cell precursor acute lymphoblastic leukemia.Haematologica. 2024 Dec 1;109(12):3835-3837. doi: 10.3324/haematol.2024.285784. Haematologica. 2024. PMID: 38988268 Free PMC article. No abstract available.
-
Differential expression and functional analysis of circular RNAs and m6A modifications in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.Sci Rep. 2025 Apr 24;15(1):13976. doi: 10.1038/s41598-025-97345-0. Sci Rep. 2025. PMID: 40274885 Free PMC article.
-
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.J Clin Oncol. 2025 Feb 10;43(5):567-577. doi: 10.1200/JCO.24.00811. Epub 2024 Nov 12. J Clin Oncol. 2025. PMID: 39531610 Free PMC article. Clinical Trial.
-
Late Complications in Long-Term Childhood Cancer Survivors: What the Oral Health Professional Needs to Know.Dent J (Basel). 2024 Jan 19;12(1):17. doi: 10.3390/dj12010017. Dent J (Basel). 2024. PMID: 38275678 Free PMC article. Review.
References
-
- Moorman AV, Antony G, Wade R, et al. : Time to cure for childhood and young adult acute lymphoblastic leukemia is independent of early risk factors: Long-term follow-up of the UKALL2003 trial. J Clin Oncol 40:4228-4239, 2022 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous